Literature DB >> 21692977

Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study.

P Fontana, R James, I Barazer, P Berdagué, J-F Schved, M Rebsamen, N Vuilleumier, J-L Reny.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21692977     DOI： 10.1111/j.1538-7836.2011.04409.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  15 in total

Review 1.  Genetics of platelet inhibitor treatment.

Authors:  Dietmar Trenk; Willibald Hochholzer
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 2.  Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).

Authors:  Thomas O Bergmeijer; Jean-Luc Reny; Ruth E Pakyz; Li Gong; Joshua P Lewis; Eun-Young Kim; Daniel Aradi; Israel Fernandez-Cadenas; Richard B Horenstein; Ming Ta Michael Lee; Ryan M Whaley; Joan Montaner; Gian Franco Gensini; John H Cleator; Kiyuk Chang; Lene Holmvang; Willibald Hochholzer; Dan M Roden; Stefan Winter; Russ B Altman; Dimitrios Alexopoulos; Ho-Sook Kim; Jean-Pierre Déry; Meinrad Gawaz; Kevin Bliden; Marco Valgimigli; Rossella Marcucci; Gianluca Campo; Elke Schaeffeler; Nadia P Dridi; Ming-Shien Wen; Jae Gook Shin; Tabassome Simon; Pierre Fontana; Betti Giusti; Tobias Geisler; Michiaki Kubo; Dietmar Trenk; Jolanta M Siller-Matula; Jurriën M Ten Berg; Paul A Gurbel; Jean-Sebastien Hulot; Braxton D Mitchell; Matthias Schwab; Marylyn DeRiggi Ritchie; Teri E Klein; Alan R Shuldiner
Journal:  Am Heart J       Date:  2017-12-17       Impact factor: 4.749

3.  The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro.

Authors:  V Ancrenaz; J Desmeules; R James; P Fontana; J-L Reny; P Dayer; Y Daali
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 4.  Recent advances in the pharmacogenetics of clopidogrel.

Authors:  Thomas Cuisset; Pierre-Emmanuel Morange; Marie-Christine Alessi
Journal:  Hum Genet       Date:  2011-12-30       Impact factor: 4.132

Review 5.  Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis.

Authors:  J-L Reny; C Combescure; Y Daali; P Fontana
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

6.  Paraoxonase 1 Q192R variant and clopidogrel efficacy: fact or fiction?

Authors:  Joshua P Lewis; Alan R Shuldiner
Journal:  Circ Cardiovasc Genet       Date:  2012-04-01

Review 7.  Monitoring aspirin and clopidogrel response: testing controversies and recommendations.

Authors:  Athanasios Karathanos; Tobias Geisler
Journal:  Mol Diagn Ther       Date:  2013-06       Impact factor: 4.074

Review 8.  The Relevance of Noncoding DNA Variations of Paraoxonase Gene Cluster in Atherosclerosis-Related Diseases.

Authors:  Anna Wysocka; Agnieszka Zwolak
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

9.  Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI.

Authors:  Kyung Woo Park; Jin Joo Park; Jeehoon Kang; Ki-Hyun Jeon; Si-Hyuck Kang; Jung-Kyu Han; Sang Eun Lee; Han-Mo Yang; Hae-Young Lee; Hyun-Jae Kang; Bon-Kwon Koo; Byung-Hee Oh; Young-Bae Park; Hyo-Soo Kim
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

10.  Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping.

Authors:  Pierre Fontana; Marco Cattaneo; Christophe Combescure; Jean-Luc Reny
Journal:  J Am Heart Assoc       Date:  2013-03-27       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.